NO973241L - Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b - Google Patents

Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b

Info

Publication number
NO973241L
NO973241L NO973241A NO973241A NO973241L NO 973241 L NO973241 L NO 973241L NO 973241 A NO973241 A NO 973241A NO 973241 A NO973241 A NO 973241A NO 973241 L NO973241 L NO 973241L
Authority
NO
Norway
Prior art keywords
treatment
hypertriglyceridemia
hypercholesterolemia
hyperlipidemia
arteriosclerosis
Prior art date
Application number
NO973241A
Other languages
English (en)
Other versions
NO973241D0 (no
Inventor
Michael Shalmi
Niels Korsgaard
Steven Bain
Birgitte Hjort Guldhammer
Jan Ulrik Weis
Charles E Hart
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO973241L publication Critical patent/NO973241L/no
Publication of NO973241D0 publication Critical patent/NO973241D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse til-veiebringer nye anvendelser av forbin-delser med den generelle formel (I). hvor,oguavhengig av hverandre er hydrogen, hydroksy, halogen, tri-fluormetyl, lavere alkyl, lavere aik-oksy eller (tertiært amino)(lavere alk-oksy); ogoguavhengig av hverandre er hydrogen eller lavere alkyl, eller som et farmasøytisk akseptabelt salt derav, i kombinasjon med en farma-søytisk akseptabel bærer, til fremstil-ling av et farmasøytisk preparat for behandling eller profylakse av hyper-lipoproteinemi, hypertriglyseridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for anti-koagulativ behandling.
NO973241A 1995-01-13 1997-07-11 Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b NO973241D0 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK4395 1995-01-13
DK4195 1995-01-13
DK6995 1995-01-20
DK76695 1995-06-30
DK76795 1995-06-30
DK77795 1995-06-30
PCT/DK1996/000014 WO1996021443A1 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment

Publications (2)

Publication Number Publication Date
NO973241L true NO973241L (no) 1997-07-11
NO973241D0 NO973241D0 (no) 1997-07-11

Family

ID=27545138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973241A NO973241D0 (no) 1995-01-13 1997-07-11 Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b

Country Status (11)

Country Link
EP (1) EP0804189A1 (no)
JP (1) JPH10511961A (no)
CN (1) CN1168098A (no)
AU (1) AU4329296A (no)
BR (1) BR9606890A (no)
CA (1) CA2208859A1 (no)
CZ (1) CZ212397A3 (no)
HU (1) HUP9800521A3 (no)
IL (1) IL116745A (no)
NO (1) NO973241D0 (no)
WO (1) WO1996021443A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
WO1999048497A1 (en) * 1998-03-20 1999-09-30 Novo Nordisk A/S USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN101056868B (zh) 2004-09-21 2012-05-02 马休爱德华兹股份有限公司 取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CA2816319C (en) 2010-11-01 2020-06-30 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
BR112016018099B8 (pt) 2014-02-07 2023-01-17 Novogen ltd Compostos funcionalizados de benzopiranos e uso dos mesmos
US10980774B2 (en) 2015-02-02 2021-04-20 Mei Pharma, Inc. Combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
JPH10511961A (ja) 1998-11-17
CN1168098A (zh) 1997-12-17
IL116745A0 (en) 1996-05-14
HUP9800521A2 (hu) 1998-12-28
BR9606890A (pt) 1997-10-28
WO1996021443A1 (en) 1996-07-18
HUP9800521A3 (en) 1999-12-28
CZ212397A3 (en) 1997-11-12
MX9705214A (es) 1997-10-31
CA2208859A1 (en) 1996-07-18
AU4329296A (en) 1996-07-31
NO973241D0 (no) 1997-07-11
IL116745A (en) 1999-12-22
EP0804189A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
PT863875E (pt) Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
SE8902326L (sv) Karboxamidfoereningar, foerfaranden foer framstaellning av dem och farmceutiska kompositioner som innehaaller dem
NO20003514L (no) Hypolipidemiske benzothiazepin-forbindelser
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
ATE306261T1 (de) Antithrombosemittel
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
YU56995A (sh) Soli derivata indola
AP9701041A0 (en) Pyridylpyrrole compounds.
BR9611400A (pt) "agentes antimicobiano de benzoxazina".
ES2147399T3 (es) Nuevos derivados de 2,3,5-trimetil-4-hidroxianilidas, su preparacion y su aplicacion terapeutica.
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
NO973241L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b
NO971625L (no) Nye peptider med immunomodulatoriske effekter
NO983178L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasaytisk preparat for behandling eller profylakse av menopausesymptomer
DK26289A (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
FI844333L (fi) 11-substituerade 5h,11h-pyrrolo/2,1-c/ /1,4/benzoxazepiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
DK0701449T3 (da) Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
NO973340L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme
DE69132578D1 (de) Cephemderivate
ES2102295B1 (es) Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
NO973242L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti
ATE216883T1 (de) Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
FI894068A (fi) Sulfonamider med tetrazolylrest, foerfarande foer deras tillverkning och laekemedel.
NO914192L (no) 8-azabicyklo(3.2.1)oktylalkylthiazolidinoner, fremgangsmaate for fremstilling og anvendelse som medikamenter